Biovail Sues FDA Over Generic Wellbutrin

Law360, New York (December 19, 2006, 12:00 AM EST) -- Scrambling to halt shipments of a generic copy of the antidepressant Wellbutrin XL, Canadian pharmaceutical company Biovail Corp. has renewed its fight against the U.S. Food and Drug Administration in another lawsuit.

Last week, the FDA cleared the way for Impax Laboratories Inc. to start selling its generic version of the drug. In a last-ditch effort, Biovail filed suit in the U.S. District Court for the District of Maryland on Monday, seeking an order rescinding FDA approval and putting a stop to shipments of the generic...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.